183 related articles for article (PubMed ID: 16011334)
1. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
3. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
[TBL] [Abstract][Full Text] [Related]
5. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
6. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
Xiao X; Cushman M
J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
[TBL] [Abstract][Full Text] [Related]
7. On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex.
Xiao X; Antony S; Pommier Y; Cushman M
J Med Chem; 2005 May; 48(9):3231-8. PubMed ID: 15857129
[TBL] [Abstract][Full Text] [Related]
8. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
9. Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.
Siu FM; Che CM
J Am Chem Soc; 2008 Dec; 130(52):17928-37. PubMed ID: 19035632
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
[TBL] [Abstract][Full Text] [Related]
11. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
Kerrigan JE; Pilch DS
Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
[TBL] [Abstract][Full Text] [Related]
12. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
13. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
14. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
15. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
16. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
18. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
Champoux JJ
Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
[TBL] [Abstract][Full Text] [Related]
19. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
20. Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.
Siu FM; Pommier Y
Nucleic Acids Res; 2013 Dec; 41(22):10010-9. PubMed ID: 24021629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
